What Are Senolytics? The Anti-Ageing Science Moving From Mouse Labs To Human Trials

There is a certain kind of cell in your body that has stopped dividing but refuses to die. It is not cancerous. It is not dead. It is something in between — a cell that has reached the end of its useful life, triggered an internal alarm, and entered a permanent state of arrested activity called cellular senescence.

In small numbers, these cells are actually useful. They appear at wound sites to help orchestrate repair. They act as a brake on the early growth of tumours. During foetal development they help shape organs. In these contexts, senescence is a feature of biology, not a bug.

But as you age, senescent cells accumulate. Your immune system — which is supposed to clear them — becomes less efficient at doing so. By the time you reach your sixties, seventies, and eighties, senescent cells are present throughout your body in significant numbers, secreting a toxic cocktail of inflammatory molecules into the surrounding tissue. This cocktail — the senescence-associated secretory phenotype, or SASP — damages neighbouring cells, disrupts tissue architecture, drives chronic inflammation, and contributes, according to a growing and compelling body of research, to virtually every major disease of ageing: heart disease, cancer, neurodegeneration, diabetes, osteoporosis, frailty.

Senescent cells are not the only cause of ageing. But they are one of its most actionable drivers. And in the past decade, a new class of drugs called senolytics — compounds that selectively kill senescent cells — have moved from mouse experiments to human clinical trials, with results that are scientifically extraordinary and, in some respects, more complicated than the early enthusiasm suggested.

This is the full story: what senescent cells are, how they damage you, what senolytics do, what the human trials have actually found, and where this field is going.

What Is Cellular Senescence? The Biology You Need to Understand

Cellular senescence is a state of stable, essentially permanent cell cycle arrest — a cell that has stopped dividing and, under normal circumstances, cannot be persuaded to start again. The term was first coined by the American cell biologists Leonard Hayflick and Paul Moorhead in 1961, when they observed that human fibroblasts in culture would divide a finite number of times — roughly 50 — and then stop, entering a state of what they called replicative senescence. The maximum number of times a cell can divide before entering this state became known as the Hayflick limit.

Since Hayflick and Moorhead’s original observation, it has become clear that cellular senescence can be triggered by many stimuli beyond telomere shortening. A 2025 review published in Cell Death Discovery from researchers at Fudan University, Temple University, and King Abdulaziz University identified the primary triggers as: DNA damage from radiation, oxidative stress, and genotoxic chemicals; telomere shortening, oxidative stress, and DNA damage as the primary triggers of cellular senescence; oncogene activation — the paradoxical situation in which the initial activation of a cancer-promoting gene triggers senescence as a protective response; and mitochondrial dysfunction, which generates reactive oxygen species that damage DNA and signal for cell cycle arrest.

At the molecular level, senescence is enforced by two primary tumour suppressor pathways: the p53/p21 pathway and the p16/Rb pathway. DNA damage and telomere shortening trigger a DNA damage response, leading to activation of the p53 transcription factor, which causes transcriptional activation of CDKN1A, and as a result p21 specifically binds to CDKs and blocks their complex formation with cyclins, ultimately resulting in cell cycle arrest and cellular senescence. The p16/Rb pathway operates in parallel, with p16 inhibiting cyclin-dependent kinases to maintain Rb in its active, growth-suppressing form. Both pathways converge on the same outcome: a cell that cannot divide.

Morphologically, senescent cells are recognisable — they are typically large, flattened, and granular in appearance. They show elevated activity of an enzyme called beta-galactosidase at pH 6, which has become one of the standard markers for identifying them in tissue. They accumulate DNA damage foci — punctate marks of persistent DNA breaks visible under the microscope. And they secrete the SASP.

The SASP: Why Senescent Cells Are So Damaging

The senescence-associated secretory phenotype is perhaps the most consequential feature of senescent cells for ageing biology. It is the mechanism through which a relatively small number of non-dividing cells can cause damage far beyond their immediate neighbourhood.

The SASP is a complex mixture of secreted factors: pro-inflammatory cytokines including IL-6, IL-8, and TNF-α; matrix metalloproteinases that degrade the extracellular matrix; growth factors including VEGF; and chemokines that recruit immune cells. Senescent cells accumulate across multiple tissues with advancing age and secrete complex mixtures of cytokines, growth factors, and proteases that reshape tissue microenvironments and propagate inflammatory signalling locally and systemically.

The consequences are wide-ranging. Locally, the SASP degrades the structural environment around the senescent cell, disrupts the function of neighbouring healthy cells, and can induce senescence in those neighbours through a process called paracrine senescence — essentially spreading the senescent state from cell to cell. Systemically, SASP factors enter the bloodstream and contribute to the state of chronic low-grade inflammation that characterises ageing — sometimes called inflammaging — which is now recognised as a major driver of age-related disease across virtually every organ system.

Increasing evidence indicates that SASP composition is highly heterogeneous and depends on cell lineage, metabolic state, and the nature of the senescence-inducing stressor. Recent discoveries demonstrate that inflammatory signalling in senescent cells is sustained by multiple nucleic acid-sensing pathways, including both cGAS-STING-dependent DNA sensing and mitochondrial RNA-mediated activation of RIG-I-like receptors. This heterogeneity — the fact that SASP is not a single fixed cocktail but a variable mixture that differs by cell type, tissue, and the history of the senescent cell — is one of the reasons that targeting senescence therapeutically is more complicated than it initially appeared.

Senescent cells also deploy immune-evasion mechanisms that limit clearance by cytotoxic lymphocytes and natural killer cells, facilitating their persistence within ageing tissues. This immune evasion — senescent cells actively suppressing the immune surveillance that should remove them — is part of why they accumulate with age even as the immune system remains partially functional. It is also part of why purely immunological approaches to clearing them may be insufficient on their own.

The Mouse Experiments That Changed Everything

The case for targeting senescent cells as a therapeutic strategy was built primarily on a remarkable series of mouse experiments conducted at the Mayo Clinic by James Kirkland, Jan van Deursen, and their collaborators, beginning around 2011.

The landmark experiment, published in Nature in 2011 by van Deursen’s group, used a genetically engineered mouse in which senescent cells could be selectively eliminated. The mice expressed a suicide gene specifically in cells expressing p16Ink4a — a marker of senescent cells — that could be activated by a drug, causing those cells to die. When the drug was administered to aged mice, clearing their senescent cells, the animals showed remarkable improvements: delayed onset of age-related conditions including cataracts, muscle wasting, and fat tissue dysfunction. Clearing senescent cells did not just slow ageing — it appeared to reverse some of its features in animals that had already aged.

Subsequent experiments were even more striking. In 2016, Kirkland’s group at Mayo showed that transplanting small numbers of senescent cells into young, healthy mice caused them to develop physical dysfunction, reduced mobility, and other features of ageing — evidence that senescent cells are not merely a correlate of ageing but a causal driver of it. When senescent cells were cleared from naturally aged mice using early senolytic compounds, the animals showed improved physical function, reduced inflammation, and extended healthspan — the period of healthy, active life.

These results generated enormous excitement in the ageing research community. The potential implication — that a drug capable of clearing senescent cells might delay or reverse multiple age-related diseases simultaneously — was one of the most promising ideas in the history of geroscience. The search for such drugs became intense.

What Are Senolytics? The Drugs Being Developed

Senolytics are compounds that selectively induce apoptosis — programmed cell death — in senescent cells, while leaving healthy non-senescent cells relatively unaffected. The selectivity arises from the biology of senescence itself: senescent cells, despite being growth-arrested, are resistant to the normal cell death signals that healthy cells respond to, because they upregulate pro-survival pathways that protect them from apoptosis. Senolytic drugs target these survival pathways.

The first senolytic compounds to be identified were dasatinib — a tyrosine kinase inhibitor already approved for leukaemia — and quercetin, a naturally occurring plant flavonoid. Dasatinib targets pro-survival signals in specific senescent cell types, particularly fat cell progenitors. Quercetin targets different pro-survival pathways across a broader range of cell types. Together, the combination known as D+Q showed greater senolytic activity than either compound alone and became the most widely studied senolytic regimen.

Recent advances in senotherapeutics have led to two principal strategies for targeting senescent cells: senolytics, which selectively induce their apoptosis, and senomorphics, which modulate deleterious aspects of the senescence phenotype, including the SASP, without removing the cells.

The distinction between senolytics and senomorphics matters. Senomorphics — which include rapamycin and certain JAK inhibitors — reduce the damage caused by senescent cells without eliminating them, by suppressing SASP secretion. They are generally better tolerated than senolytics but do not address the underlying accumulation of dysfunctional cells. Senolytics aim to eliminate the problem at its source.

Other senolytic compounds now in various stages of development include:

Navitoclax (ABT-263) — a BCL-2 family inhibitor that showed potent senolytic activity in preclinical studies but causes thrombocytopenia (dangerous reduction in platelets) as a side effect in humans, limiting its clinical utility in its current form
Fisetin — a naturally occurring flavonoid with senolytic properties being investigated in multiple clinical trials, including in older adults and in frailty
17-DMAG — an HSP90 inhibitor with senolytic activity
UBX0101 — a MDM2/p53 interaction inhibitor developed by Unity Biotechnology, which completed a Phase 2 trial for osteoarthritis of the knee
CAR-T cell-based senolytics — engineered immune cells that recognise and destroy senescent cells expressing specific surface markers, developed by researchers at the Salk Institute and Cold Spring Harbor Laboratory

What Human Clinical Trials Have Actually Found — The Honest Picture

The transition from remarkable mouse results to human clinical trials has produced a picture that is scientifically important, genuinely promising in some respects, and considerably more complicated than the initial enthusiasm suggested.

The good news: safety and biological activity. A new study by researchers from Harvard Medical School, the Mayo Clinic, Cedars-Sinai Medical Center, Beth Israel Deaconess Medical Center, and the Hinda and Arthur Marcus Institute for Aging Research found that the treatment appeared to be both feasible and safe.

There were no serious adverse events reported, which is a critical finding for any new therapeutic approach. The study evaluated intermittent D+Q dosing — two days on, twelve days off — over twelve weeks in older adults at risk for Alzheimer’s disease, as part of the STAMINA trial. The compounds were administered for just two days every two weeks, over a total period of 12 weeks. This intermittent dosing strategy is based on preclinical studies suggesting that senolytics do not need to be continuously present to be effective.

The SToMP-AD trial, evaluating D+Q in patients with symptomatic Alzheimer’s disease, and the STAMINA trial together provide the most detailed human data on senolytics in neurodegeneration. Plasma levels of dasatinib and quercetin increased in all SToMP participants, and dasatinib was detected in cerebrospinal fluid in 80% of participants, confirming CNS exposure. In SToMP, plasma inflammatory markers — including factors of the senescence-associated secretory phenotype — decreased following treatment. In STAMINA, reductions in plasma TNF-α significantly correlated with improvements in MoCA cognitive scores.

The complicated news: clinical outcomes are modest. An NIA-funded clinical trial investigating whether a senolytic drug combination could improve bone health in older women found just limited benefits compared to a control group. Published in Nature Medicine, these findings suggest that using senolytic products to reverse the effects of ageing in humans has just a subtle effect despite earlier promising evidence from mouse studies. The trial — a Phase 2 randomised controlled study by researchers including Jon Farr at Mayo Clinic — was the largest and most rigorous senolytic trial to date, and its modest results were sobering.

The results of clinical trials remain mitigated while the necessity to eliminate senescent cells is still present, highlighting the fact that several modifications in terms of strategy are essential to improve patients’ lifespan.

Unity Biotechnology’s UBX0101 for osteoarthritis of the knee failed to show significant benefit over placebo in its Phase 2 trial — a significant setback for the field that led to the programme being discontinued.

What explains the gap between dramatic mouse results and more modest human outcomes? Several factors are likely relevant. Mice are not humans — the senescent cell burden in aged mice relative to body size is very different from the situation in humans. The duration of trials may be insufficient to detect effects on long-term outcomes. The patient populations selected may not have had sufficiently high senescent cell burden to show dramatic responses. And the SASP heterogeneity highlighted in recent research — its variability by cell type, tissue, and senescence-inducing stressor — means that a single drug combination may not adequately address the full spectrum of senescent cell types contributing to a given disease.

The Next Generation: CAR-T Senolytics and Immune-Based Approaches

The limitations of first-generation small molecule senolytics have accelerated the development of more targeted approaches that exploit the specific surface markers displayed by senescent cells.

In 2023, researchers at Cold Spring Harbor Laboratory published in Nature Aging a remarkable proof-of-concept study showing that CAR-T cells — the engineered immune cells that have transformed leukaemia treatment — could be designed to target and destroy senescent cells expressing the surface protein uPAR, which is upregulated in many types of senescent cells. In mouse models, CAR-T senolytics improved metabolic function, extended healthspan, and showed no apparent toxicity. In a mouse model of lung adenocarcinoma, CAR-T senolytics reduced tumour burden — exploiting the senescence that cancer therapy induces in tumour cells.

The Salk Institute group led by Juan Carlos Izpisua Belmonte has pursued a related strategy — partial cellular reprogramming using Yamanaka factors to reset the epigenetic age of cells, partially reversing senescence without fully dedifferentiating them. Their 2023 work published in Nature Aging demonstrated lifespan extension in progeria mice, though the translational path to humans remains long.

New therapeutic strategies have been developed particularly with the evolution of immunotherapies, which should provide better results than first-generation small molecule senolytics. The immune system’s own senescence-surveillance machinery — natural killer cells and cytotoxic T lymphocytes — can be enhanced or supplemented rather than bypassed. Several groups are developing approaches to restore the immune system’s ability to clear senescent cells as it does in younger individuals, rather than relying on exogenous drugs to do the job.

Senolytics and Specific Diseases: The Pipeline

The senolytic clinical trial pipeline now spans a remarkable range of conditions, reflecting the broad role of cellular senescence in age-related pathology.

Alzheimer’s disease and neurodegeneration. DNA damage, oxidative stress, and telomere shortening are primary triggers of cellular senescence in the brain, and senescent cells — including senescent astrocytes, microglia, and neurons — accumulate in the ageing brain and in the brains of Alzheimer’s patients. The SToMP-AD and STAMINA trials have established biological proof-of-concept that D+Q reaches the CNS and reduces SASP markers. Larger efficacy trials are in planning.

Osteoporosis and musculoskeletal disease. Evidence suggests that it is feasible to alleviate chronic age-related disorders by targeting the biology of ageing. Recent studies implicate cellular senescence at the nexus of skeletal ageing, suggesting that selectively eliminating senescent cells may emerge as a conceptually novel approach to manage the enormous problem of age-related bone loss. The Phase 2 Nature Medicine trial showed modest effects on bone resorption markers, but multiple other trials in osteoporosis and musculoskeletal conditions remain active.

Pulmonary fibrosis. The Mayo Clinic completed the first human senolytic trial in patients with idiopathic pulmonary fibrosis — a progressive and usually fatal lung-scarring disease with strong senescence involvement — and showed improvements in physical function measures that suggested biological activity, though the trial was small and open-label.

Chronic kidney disease, cardiovascular disease, diabetes. Ding et al. established cellular senescence as both a cause and consequence of metabolic dysfunction, with visceral adipose tissue serving as a major source of SASP factors that propagate systemic inflammation and impair insulin signalling. They systematically review senescence accumulation in pancreatic beta-cells, diabetic kidney disease, and cardiovascular complications, while critically evaluating the therapeutic potential of senolytics in metabolic disease. Trials in these areas are underway, though most are early-phase.

COVID-19 long-term effects. Emerging evidence suggests that SARS-CoV-2 infection induces cellular senescence in lung and other tissues, potentially contributing to the persistent symptoms of long COVID. Senolytic trials in this population have been initiated.

The Honest Assessment: Where Are We Really?

It would be easy, surveying the field in mid-2026, to tell two very different stories about senolytics. The optimistic story is that a new class of drugs is showing biological proof-of-concept in humans, that the science pointing to senescent cells as causal drivers of ageing is robust, and that the field is moving rapidly from proof-of-concept toward efficacy trials. The cautious story is that first-generation compounds have shown modest clinical effects at best, that the dramatic mouse results have not translated cleanly, and that significant challenges in delivery, specificity, and biomarker identification remain.

Both stories are true. And the honest position is that the field is at an early stage — perhaps where cancer immunotherapy was in the early 2000s, when early checkpoint inhibitor trials were showing biological activity and modest responses, years before the field matured into the transformative cancer treatment it has become.

The key challenges the field needs to solve are:

Biomarkers — reliable, measurable indicators of senescent cell burden that can be used to select patients most likely to respond and to confirm that a drug is having its intended effect. Current candidates include p16 mRNA in blood, SASP factors, and imaging of senescence markers in tissue, but none is yet validated for clinical use.
Selectivity — ensuring that senolytic compounds kill senescent cells without damaging important healthy cell populations. The thrombocytopenia seen with navitoclax illustrates the risk. Next-generation approaches — CAR-T cells, targeted antibody-drug conjugates — aim to address this through greater molecular precision.
Tissue access — ensuring that senolytic compounds reach the relevant tissues in sufficient concentrations. The CNS penetration data from SToMP-AD is encouraging for brain-targeted applications, but access to other tissues remains a challenge for some compounds.
SASP heterogeneity — understanding that different senescent cell types in different tissues drive different aspects of age-related pathology, and that one-size-fits-all senolytic strategies may need to give way to tissue-specific or disease-specific approaches.

The connection between senolytics and the broader landscape of genetics research is direct. Senescent cells accumulate partly because DNA repair mechanisms — which are fundamental to maintaining genome integrity — become less efficient with age. Telomere shortening, one of the primary triggers of senescence, is the subject of intense current research into both its mechanisms and its potential manipulation.

For the full story of telomeres and what they reveal about the molecular biology of ageing, see our article on telomeres and ageing: the genetic clocks inside every cell. And for the broader picture of how DNA damage and repair connect to cancer — the disease in which senescence plays its most complex role — see our article on the genetics of cancer: how DNA mutations drive the disease.

Epigenetic changes — alterations in the chemical marks that control gene expression — are both a cause and a consequence of cellular senescence. Senescent cells show characteristic patterns of epigenetic dysregulation, and the epigenetic clock measures developed by Steve Horvath and others, which estimate biological age from DNA methylation patterns, are strongly influenced by senescent cell burden. For the story of how epigenetics connects to ageing and disease, see our article on epigenetics: how your environment shapes the way your genes work.

Frequently Asked Questions

What are senescent cells?

Senescent cells are cells that have permanently stopped dividing — triggered by DNA damage, telomere shortening, oxidative stress, or oncogene activation — but have not died. They accumulate with age and secrete a damaging mixture of inflammatory molecules called the SASP that harms neighbouring cells, disrupts tissue function, and drives chronic inflammation. While small numbers of senescent cells serve useful functions in wound healing and tumour suppression, their accumulation in ageing tissues is associated with multiple age-related diseases.

What are senolytics?

Senolytics are drugs that selectively kill senescent cells by targeting the pro-survival pathways these cells upregulate to resist normal cell death signals. The most studied senolytic combination is dasatinib and quercetin (D+Q). Other candidates include fisetin, navitoclax, and CAR-T cell-based approaches. Senolytics are distinct from senomorphics, which suppress the harmful secretions of senescent cells without eliminating them.

Have senolytics been tested in humans?

Yes. Multiple Phase 1 and Phase 2 clinical trials have evaluated senolytic compounds in humans for conditions including Alzheimer’s disease, osteoporosis, pulmonary fibrosis, osteoarthritis, and chronic kidney disease. Results have confirmed safety and biological activity — including reductions in SASP inflammatory markers — but clinical benefit in efficacy trials has been modest so far. Larger trials are ongoing.

What is the SASP?

The senescence-associated secretory phenotype is the complex mixture of inflammatory cytokines, matrix-degrading enzymes, and growth factors that senescent cells secrete into their surrounding tissue. SASP factors include IL-6, IL-8, TNF-α, and matrix metalloproteinases. The SASP damages neighbouring cells, recruits inflammatory immune cells, and can spread senescence from cell to cell. It is the primary mechanism through which senescent cells cause harm in ageing tissues.

Why do mouse results not always translate to humans?

Several factors explain the gap. Mice age much faster than humans and may have a higher relative senescent cell burden at the time of treatment. Clinical trials in humans use patient populations with specific diseases rather than the healthspan endpoints used in mice. Trial durations may be insufficient for functional outcomes to emerge. And the heterogeneity of SASP composition across different senescent cell types may mean that single drug combinations do not adequately address the full spectrum of senescent cells in human disease.

Are senolytics available as supplements?

Quercetin and fisetin — two compounds with senolytic properties — are widely available as nutritional supplements. However, the doses used in clinical trials are substantially higher than those in typical supplements, and the evidence from human trials for clinically meaningful benefits is still limited. Taking these compounds as supplements is not the same as receiving a validated senolytic treatment and should not be assumed to replicate trial results. Consult a physician before taking any compound for anti-ageing purposes.

Sources

About the Author

Baryon is the founder and editor of Web News For Us. Driven by a deep fascination with the biggest unanswered questions in science — from quantum physics and cosmology to the nature of consciousness and the genetic code written into every living cell — he has spent years studying modern physics, biology, and the history of scientific thought. He covers Science & AI, Space, Genetics & Research, and the timeless wisdom of history’s greatest thinkers and mystics.

If you have ever looked at the night sky and felt that pull to understand what is out there or wondered about an entire universe coiled inside your genes, you are in the right place.